Skip to main content Accessibility help
×
Hostname: page-component-7bb8b95d7b-495rp Total loading time: 0 Render date: 2024-09-10T18:08:51.972Z Has data issue: false hasContentIssue false

20 - Management commentary

Published online by Cambridge University Press:  13 August 2009

Philip B. Mitchell
Affiliation:
School of Psychiatry, University of New South Wales Black Dog Institute, Sydney, Australia
Gordon Parker
Affiliation:
University of New South Wales, Sydney
Get access

Summary

It is a difficult task to comment upon an individual's clinical model for treating ‘Bipolar II Disorder’ (BP II) without clarity about the criteria being used to make that diagnosis. In contemporary academic and clinical practice there is a myriad of definitions for BP II, each with associated stated and unstated connotations. There is a consequent unfortunate conflation in the use of this term, with the implicit message that ‘all Bipolar II Disorder is the same’. This is in fact not true, as a quick reflection on the historical origins of the use of this term would indicate. The term ‘Bipolar II Disorder’ was originally coined by Fieve and Dunner (1975) to describe an attenuated form of classical bipolar disorder/manic depressive illness in which the elevated component of the illness was less severe than in Bipolar I Disorder (BP I). This concept of BP II, which became enshrined in the RDC and DSM nosological systems, and incorporates minimum durations of hypomania varying from 2 to 7 days, has been validated by being demonstrated to be genetically related to BP I.

A more recent usage has stemmed from the broad concept of the ‘soft bipolar spectrum’ (Akiskal and Mallya, 1987), in which conceptualisation of BP II has been extended to include brief hypomanic episodes as well as cyclothymic and hyperthymic personality traits (Akiskal et al., 2000).

Type
Chapter
Information
Bipolar II Disorder
Modelling, Measuring and Managing
, pp. 244 - 246
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Akiskal, H. S., Bourgeois, M. L., Angst, J.et al. (2000). Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders, 59 (Suppl. 1), S5–30.CrossRefGoogle ScholarPubMed
Akiskal, H. S. and Mallya, G. (1987). Criteria for the ‘soft’ bipolar spectrum: treatment implications. Psychopharmacology Bulletin, 23, 68–73.Google ScholarPubMed
Altshuler, L. L., Suppes, T., Black, D. O.et al. (2006). Lower switch rate in depressed patients with Bipolar II than Bipolar I Disorder treated adjunctively with second-generation antidepressants. American Journal of Psychiatry, 163, 313–15.CrossRefGoogle ScholarPubMed
Fieve, R. R. and Dunner, D. L. (1975). Unipolar and bipolar affective states. In The Nature and Treatment of Depression, ed. Flach, F. F. and Draghi, S. S., pp. 145–60. New York: John Wiley and Sons.Google Scholar
Hadjipavlou, G., Mok, H. and Yatham, L. N. (2004). Pharmacotherapy of Bipolar II Disorder: a critical review of current evidence. Bipolar Disorders, 6, 14–25.CrossRefGoogle ScholarPubMed
Parker, G., Tully, L. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.CrossRefGoogle ScholarPubMed
RANZCP Clinical Practice Treatment Guideline on Bipolar Disorder (2004). Australian and New Zealand Journal of Psychiatry, 38, 280–305.CrossRef
Rich, B. A., Schmajuk, M., Perez-Edgar, K. E.et al. (2007). Different psychophysiological and behavioral responses elicited by frustration in pediatric bipolar disorder and severe mood dysregulation. American Journal of Psychiatry, 164, 309–17.CrossRefGoogle ScholarPubMed
Thase, M. E., Macfadden, W., Weisler, R. H.et al. (2006). Efficacy of quetiapine monotherapy in Bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER study). Journal of Clinical Psychopharmacology, 26, 600–9.CrossRefGoogle Scholar
Zarate, C. A. Jr., Payne, J. L., Singh, J.et al. (2004). Pramipexole for Bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 56, 54–60.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Management commentary
    • By Philip B. Mitchell, School of Psychiatry, University of New South Wales Black Dog Institute, Sydney, Australia
  • Edited by Gordon Parker, University of New South Wales, Sydney
  • Book: Bipolar II Disorder
  • Online publication: 13 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544187.022
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Management commentary
    • By Philip B. Mitchell, School of Psychiatry, University of New South Wales Black Dog Institute, Sydney, Australia
  • Edited by Gordon Parker, University of New South Wales, Sydney
  • Book: Bipolar II Disorder
  • Online publication: 13 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544187.022
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Management commentary
    • By Philip B. Mitchell, School of Psychiatry, University of New South Wales Black Dog Institute, Sydney, Australia
  • Edited by Gordon Parker, University of New South Wales, Sydney
  • Book: Bipolar II Disorder
  • Online publication: 13 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544187.022
Available formats
×